THE WOODLANDS, Texas, Jan. 3, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has completed dosing in its Phase 2 low-dose trial of oral Proellex intended for the treatment of symptoms of uterine fibroids and endometriosis. A particular focus in the present study, also known as ZP-204, was evaluation of induction of amenorrhea (cessation of menses) where doses as low as 3 mg were found effective.
